Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Response Adapted Lenalidomide Based Therapy For Newly Diagnosed (ND) Standard Risk Older Adults With Multiple Myeloma (MM): An International Collaboration

Rachid Baz, MD, Hui-Yi Lin, PhD, Sung-Soo Yoon, MD, Kihyun Kim, MD, Melissa Alsina, MD, Kenneth H. Shain, MD, PhD, Dan Sullivan, MD, Hye Jin Kang, Jin Seok Kim, MD, Cheolwon Suh, Je-Jung Lee, MD, PhD, Jeong-A Kim, MD, PhD, Yang Soo Kim, MD, Chang-Ki Min, MD, Jae-Yong Kwak, MD, PhD, Sung-Hyun Kim, MD, PhD, Won Sik Lee, MD, Junshik Hong, MD, Jae Hoon Lee, MD

Blood (2013) 122 (21): 3201.

https://doi.org/10.1182/blood.V122.21.3201.3201

Published: 2013

Journal Articles

A Phase 2 Study of Bortezomib Plus High-Dose Melphalan (Mel/Vel) Conditioning for Autologous Hematopoietic Cell Transplantation In Multiple Myeloma,

Taiga Nishihori, MD, Leonel Ochoa, Joseph Pidala, MD, MS, Kenneth H. Shain, MD, PhD, Rachid Baz, MD, Christine Simonelli, RN, Dan Sullivan, Claudio Anasetti, MD, Melissa Alsina, MD

Blood (2011) 118 (21): 4158.

https://doi.org/10.1182/blood.V118.21.4158.4158

Published: 2011

Journal Articles

Hypoalbuminemia (< 3.0 g/dl) and Poor Karnofsky Performance Score (<80) at Day 90 Following Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Are Independent Predictors of Worse Non-Relapse Survival (NRS) and Overall Survival (OS): A Multivariable Analysis Approach of Various Clinical, Laboratory and Pharmacologic Parameters

Mohamed A Kharfan-Dabaja, MD, Julio C. Chavez, Eduardo Ivan Fernandez-Vertiz, Daohai Yu, Weiwei Zhu, Janelle Perkins, Teresa Field, Ernesto Ayala, Hugo F. Fernandez, Melissa Alsina, Lia Perez, Jyotishankar Raychaudhuri, J. Leonel Ochoa-Bayona, Linda Brand, Dan Sullivan, Claudio Anasetti

Blood (2008) 112 (11): 4329.

https://doi.org/10.1182/blood.V112.11.4329.4329

Published: 2008

Journal Articles

Administration of Rituximab 375 Mg/m2 on Days +1 and +8 after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Regimens for Patients with Advanced CD20+ Lymphoid Malignancies

Mohamed A Kharfan-Dabaja, MD, Cheryl Tate, Janelle Perkins, Teresa Field, Hugo F. Fernandez, Melissa Alsina, Ernesto Ayala, Jyotishankar Raychaudhuri, Lia Perez, J. Leonel Ochoa-Bayona, Linda Brand, Javier Pinilla-Ibarz, Eduardo Sotomayor, Dan Sullivan, Claudio Anasetti

Blood (2008) 112 (11): 4323.

https://doi.org/10.1182/blood.V112.11.4323.4323

Published: 2008

Journal Articles

A Randomized, Controlled Trial of Graft-Versus-Host Disease (GVHD) Prophylaxis Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate: Analysis of GVHD, Relapse and Survival.

Janelle Perkins, Melissa Alsina, Claudio Anasetti, Ernesto Ayala, Hugo F. Fernandez, Mohamed Kharfan-Dabaja, Jose Leonel Ochoa-Bayona, Lia Perez, Jyotishankar Raychaudhuri, Dan Sullivan, Jongphil Kim, Michael Schell, Teresa Field

Blood (2008) 112 (11): 2235.

https://doi.org/10.1182/blood.V112.11.2235.2235

Published: 2008

Journal Articles

Administration of Rituximab Is Feasible and Does Not Affect Engraftment of Allograft Recipients with Advanced CD20+ Malignancies.

Mohamed A. Kharfan-Dabaja, MD, Cheryl Tate, PharmD, Janelle Perkins, PhD, Hugo F. Fernandez, MD, Teresa Field, MD, Ernesto Ayala, MD, Lia Perez, MD, Jyotishankar Raychaudhuri, MD, Melissa Alsina, MD, Dan Sullivan, MD, Linda Brand, RN, William Poling, PhD, Claudio Anasetti, MD

Blood (2007) 110 (11): 3016.

https://doi.org/10.1182/blood.V110.11.3016.3016

Published: 2007

Journal Articles

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Two Doses of Bortezomib (Btz) in Patients with Relapsed Multiple Myeloma (MM).

A. Keith Stewart, MB, ChB, Dan Sullivan, MD, Sagar Lonial, MD, Ann F. Mohrbacher, MD, Gurkamal Chatta, MD, Chaim Shustik, MD, Howard Burris, III, Michael Karol, PhD, Peter Zannikos, PhD, Donna E. Reece, MD

Blood (2006) 108 (11): 3533.

https://doi.org/10.1182/blood.V108.11.3533.3533

Published: 2006

NARROW

Response Adapted Lenalidomide Based Therapy For Newly Diagnosed (ND) Standard Risk Older Adults With Multiple Myeloma (MM): An International Collaboration

A Phase 2 Study of Bortezomib Plus High-Dose Melphalan (Mel/Vel) Conditioning for Autologous Hematopoietic Cell Transplantation In Multiple Myeloma,

Administration of Rituximab 375 Mg/m2 on Days +1 and +8 after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Regimens for Patients with Advanced CD20+ Lymphoid Malignancies

A Randomized, Controlled Trial of Graft-Versus-Host Disease (GVHD) Prophylaxis Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate: Analysis of GVHD, Relapse and Survival.

Administration of Rituximab Is Feasible and Does Not Affect Engraftment of Allograft Recipients with Advanced CD20+ Malignancies.

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Two Doses of Bortezomib (Btz) in Patients with Relapsed Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Response Adapted Lenalidomide Based Therapy For Newly Diagnosed (ND) Standard Risk Older Adults With Multiple Myeloma (MM): An International Collaboration

A Phase 2 Study of Bortezomib Plus High-Dose Melphalan (Mel/Vel) Conditioning for Autologous Hematopoietic Cell Transplantation In Multiple Myeloma,

Administration of Rituximab 375 Mg/m2 on Days +1 and +8 after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Regimens for Patients with Advanced CD20+ Lymphoid Malignancies

A Randomized, Controlled Trial of Graft-Versus-Host Disease (GVHD) Prophylaxis Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate: Analysis of GVHD, Relapse and Survival.

Administration of Rituximab Is Feasible and Does Not Affect Engraftment of Allograft Recipients with Advanced CD20+ Malignancies.

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Two Doses of Bortezomib (Btz) in Patients with Relapsed Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only